Hexavalent IPV-based combination vaccines for public-sector markets of low-resource countries

References

• World Health Assembly. Global eradication of poliomyelitis by the year 2000 (resolution 41.28). May 1988; Geneva. Available at: http://www.who.int/ihr/polioresolution4128en.pdf.
   Google Scholar
• World Health Organization. Meeting of the Strategic Advisory Group of Experts on Immunization, November 2012 – conclusions and recommendations. Wkly Epidemiol Rec 2013; 88:1 - 16; PMID: 23311010
   PubMedGoogle Scholar
• Patriarca PA, Sutter RW, Oostvogel PM. Outbreaks of paralytic poliomyelitis, 1976-1995. J Infect Dis 1997; 175:Suppl 1 S165 - 72; http://dx.doi.org/10.1093/infdis/175.Supplement_1.S165; PMID: 9203711
   PubMed Web of Science ®Google Scholar
• INFANRIX® hexa (version 4.0). GSK. May 10, 2012. Available at: http://www.gsk.com.au/resources.ashx/vaccineproductschilddataproinfo/362/FileName/D58F401484B3F7CD68FBC0A2D3A1D77D/Infanrix_Hexa_(Preservative_containing)_v4_0_clean_PDF.pdf.
   Google Scholar
• Summary of opinion on hexaxim. European Medicines Agency. June 21, 2012. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/Other/2012/06/WC500129095.pdf.
   Google Scholar
• Witt MA, Katz PH, Witt DJ. Unexpectedly limited durability of immunity following acellular pertussis vaccination in preadolescents in a North American outbreak. Clin Infect Dis 2012; 54:1730 - 5; http://dx.doi.org/10.1093/cid/cis287; PMID: 22423127
   PubMed Web of Science ®Google Scholar
• Sheridan SL, Ware RS, Grimwood K, Lambert SB. Number and order of whole cell pertussis vaccines in infancy and disease protection. JAMA 2012; 308:454 - 6; http://dx.doi.org/10.1001/jama.2012.6364; PMID: 22851107
   PubMed Web of Science ®Google Scholar
• Pichichero ME, Green JL, Francis AB, Marsocci SM, Murphy AM, Buscarino C. Antibody response and reactions to completion of a four-dose series with a two- or three-component acellular pertussis vaccine compared to whole cell pertussis vaccine. Scand J Infect Dis 1996; 28:159 - 63; http://dx.doi.org/10.3109/00365549609049068; PMID: 8792483
   PubMed Web of Science ®Google Scholar
• Pichichero ME, Rennels MB, Edwards KM, Blatter MM, Marshall GS, Bologa M, et al. Combined tetanus, diphtheria, and 5-component pertussis vaccine for use in adolescents and adults. JAMA 2005; 293:3003 - 11; http://dx.doi.org/10.1001/jama.293.24.3003; PMID: 15933223
   PubMed Web of Science ®Google Scholar
• Sturgess AW, Rush K, Charbonneau RJ, Lee JI, West DJ, Sitrin RD, et al. Haemophilus influenzae type b conjugate vaccine stability: catalytic depolymerization of PRP in the presence of aluminum hydroxide. Vaccine 1999; 17:1169 - 78; http://dx.doi.org/10.1016/S0264-410X(98)00337-5; PMID: 10195629
   PubMed Web of Science ®Google Scholar
• Tregnaghi MW, Zambrano B, Santos-Lima E. Immunogenicity and safety of an investigational hexavalent diphtheria-tetanus-acellular pertussis-inactivated poliovirus-hepatitis B-Haemophilus influenzae B conjugate combined vaccine in healthy 2-, 4-, and 6-month-old Argentinean infants. Pediatr Infect Dis J 2011; 30:e88 - 96; PMID: 21372751
   PubMed Web of Science ®Google Scholar
• Kosalaraksa P, Thisyakorn U, Benjaponpitak S, Chokephaibulkit K, Santos-Lima E. Immunogenicity and safety study of a new DTaP-IPV-Hep B-PRP-T combined vaccine compared to a licensed DTaP-IPV-Hep B//PRP-T comparator, both concomitantly administered with a 7-valent pneumococcal conjugate vaccine at 2, 4, and 6 months of age in Thai infants. Int J Infect Dis 2011; 15:e249 - 56; http://dx.doi.org/10.1016/j.ijid.2010.12.004; PMID: 21334243
   PubMed Web of Science ®Google Scholar
• Merck pipeline vaccines. MERCK. February 22, 2013. Available at: http://www.merck.com/research/pipeline/home.html.
   Google Scholar
• Diphtheria-tetanus-pertussis (whole cell)-hepatitis b-haemophilus influenzae type b (1 dose vial). World Health Organization. September 7, 2012. Available at: http://www.who.int/immunization_standards/vaccine_quality/07_dtphephib/en/index.html.
   Google Scholar
• Quiambao B, Van Der Meeren O, Kolhe D, Gatchalian S. A randomized, dose-ranging assessment of the immunogenicity and safety of a booster dose of a combined diphtheria-tetanus-whole cell pertussis-hepatitis B-inactivated poliovirus-Haemophilus influenzae type b (DTPw-HBV-IPV/Hib) vaccine vs. co-administration of DTPw-HBV/Hib and IPV vaccines in 12 to 24 months old Filipino toddlers. Hum Vaccin Immunother 2012; 8:347 - 54; http://dx.doi.org/10.4161/hv.18630; PMID: 22330958
   PubMed Web of Science ®Google Scholar
• Thalen M, van der Ark A, van den Ijssel J, van Straaten I, Jansen D, Beuvery C, et al. Improving the cellular pertussis vaccine: increased potency and consistency. Vaccine 2008; 26:653 - 63; http://dx.doi.org/10.1016/j.vaccine.2007.11.047; PMID: 18155325
   PubMed Web of Science ®Google Scholar
• Quadrivalent vaccine TAK-361S enters into phase II clinical trials in Japan. Takeda Pharmaceutical Company Limited. 2011. Available at: http://www.takeda.com/news/2011/20111116_3913.html.
   Google Scholar
• Quinvaxem®. Crucell. August 15, 2012. Available at: http://www.crucell.com/Products-Quinvaxem.
   Google Scholar
• Wyman O. Supply landscape and economics of IPV-containing combination vaccines: key findings. Commissioned by the Bill & Melinda Gates Foundation; 2010. Available at: http://www.polioeradication.org/Portals/0/Document/Resources/SupplyLandscapeEconomics.09.06.2010.pdf.
   Google Scholar
• Sawyer LA, McInnis J, Patel A, Horne AD, Albrecht P. Deleterious effect of thimerosal on the potency of inactivated poliovirus vaccine. Vaccine 1994; 12:851 - 6; http://dx.doi.org/10.1016/0264-410X(94)90296-8; PMID: 7526574
   PubMed Web of Science ®Google Scholar
• Diphtheria-Tetanus-Pertussis (whole cell)-Haemophilus influenzae type b (10 dose vial). World Health Organization. September 7, 2012. Available at: http://www.who.int/immunization_standards/vaccine_quality/PQ_38_DTPHib_Novartis_10_dose/en/.
   Google Scholar
• Meeting report: WHO Informal Consultation (April 3-4 2012) to develop further guidance on vaccines for UNEP-convened intergovernmental negotiating committee meeting 4 (INC 4). World Health Organization. April 3, 2012. Available at: http://www.who.int/biologicals/Report_THIOMERSAL_WHO_Mtg_3-4_April_2012.pdf.
   Google Scholar
• Annex I summary of product characteristics. European Medicines Agency. April 26, 2005. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000298/WC500074586.pdf.
   Google Scholar
• Serum Institute of India Ltd. acquires Bilthoven Biologicals of Netherlands. Serum Institute of India Ltd. July 4, 2012. Available at: http://www.seruminstitute.com/content/news_9.htm.
   Google Scholar
• GSK and Biological E announce joint venture to develop combination vaccine for India and other developing countries. Business Wire India. January 28, 2013. Available at: http://www.businesswireindia.com/PressRelease.asp?b2mid=34175.
   Google Scholar
• Supplies and logistics: vaccine price data. UNICEF. April 2, 2013. Available at: http://www.unicef.org/supply/index_57476.html.
   Google Scholar
• UNICEF. Current IPV supply, recent tender results and outlook for the future. 2012. Available at: http://www.unicef.org/supply/files/IPV_Supply_Status_UNICEF-SD_v6.pdf
   Google Scholar
• World Health Organization. Meeting of the strategic advisory group of experts on immunization, April 2012 - conclusions and recommendations. Wkly Epidemiol Rec 2012; 87:201 - 16
   PubMedGoogle Scholar
• EPI routine vaccines pentavalent, hexavalent and traditional EPI vaccines. UNICEF. January 25, 2012. Available at: http://www.unicef.org/supply/files/8._DTP-containing_vaccines_including_pentavalent_and_hexavalent.pdf.
   Google Scholar
• VIMS report: global vaccine introduction. International Vaccine Access Center. March 2013. Available at: http://www.jhsph.edu/research/centers-and-institutes/ivac/vims/IVAC-VIMS-Report-2013-03.pdf.
   Google Scholar
• Mohammed AJ, AlAwaidy S, Bawikar S, Kurup PJ, Elamir E, Shaban MM, et al. Fractional doses of inactivated poliovirus vaccine in Oman. N Engl J Med 2010; 362:2351 - 9; http://dx.doi.org/10.1056/NEJMoa0909383; PMID: 20573923
   PubMed Web of Science ®Google Scholar
• Resik S, Tejeda A, Sutter RW, Diaz M, Sarmiento L, Alemañi N, et al. Priming after a fractional dose of inactivated poliovirus vaccine. N Engl J Med 2013; 368:416 - 24; http://dx.doi.org/10.1056/NEJMoa1202541; PMID: 23363495
   PubMed Web of Science ®Google Scholar
• Resik S, Tejeda A, Lago PM, Diaz M, Carmenates A, Sarmiento L, et al. Randomized controlled clinical trial of fractional doses of inactivated poliovirus vaccine administered intradermally by needle-free device in Cuba. J Infect Dis 2010; 201:1344 - 52; http://dx.doi.org/10.1086/651611; PMID: 20350164
   PubMed Web of Science ®Google Scholar